Fosamax Osteonecrosis of the Jaw Attorney: Legal Options for Fosamax (Alendronate) Lawsuits

From General Health Information to Targeted Risk Awareness

The legacy of general health and science information dissemination has long served as a foundation for public awareness, providing individuals with the knowledge needed to make informed decisions about their well-being. This heritage includes broad discussions of medication benefits, risks, and the importance of consulting healthcare professionals. Within this context, the bisphosphonate class of drugs, including alendronate (marketed as Fosamax), has been widely prescribed for conditions such as osteoporosis. General health resources have historically highlighted the therapeutic value of these medications in maintaining bone density. As public understanding evolves, a more focused concern has emerged regarding specific adverse outcomes associated with long-term bisphosphonate use. Among these, osteonecrosis of the jaw (ONJ) has become a significant topic of discussion, particularly for patients who have undergone dental procedures or have other risk factors. This shift from general health education to a targeted risk awareness naturally leads to questions about legal recourse. Individuals who have experienced ONJ after taking Fosamax may seek to understand their legal options, including the possibility of filing a lawsuit.

Understanding Fosamax and Osteonecrosis of the Jaw (ONJ)

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ typically involves pain, swelling, infection, and exposed bone in the jaw. Diagnosis is based on clinical examination and imaging, often requiring referral to an oral surgeon. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors and Mechanisms Linking Fosamax to ONJ

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ are not fully detailed in the provided evidence, but bisphosphonates like alendronate inhibit bone resorption by suppressing osteoclast activity. This suppression can reduce bone turnover and impair the jaw's ability to heal after dental procedures or infection, potentially leading to ONJ. The evidence notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Legal Considerations for Fosamax Users Who Developed ONJ

From a legal perspective, patients who have developed ONJ after using Fosamax may consider consulting an attorney to explore their options. Key considerations include the adequacy of warnings provided by the manufacturer. The Fosamax label includes a warning about ONJ, stating that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, patients may question whether the warnings were sufficient to inform them of the risk, especially given that ONJ can occur spontaneously and the time to onset can vary widely. The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that the manufacturer recognized the risk and provided guidance, but the adequacy of these warnings in practice may be subject to legal scrutiny. Attorney-related considerations for affected patients include the need to document the timeline between exposure to Fosamax and the development of ONJ. The evidence indicates that the time to onset of symptoms can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability may complicate legal claims, as establishing a direct causal link requires careful medical and chronological documentation. Patients should also consider that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), meaning longer-term users may have a stronger basis for a claim.

Additional Adverse Reactions and Clinical Guidance

In addition to ONJ, the Fosamax label reports other adverse reactions, including musculoskeletal pain (bone, muscle, or joint pain), which was considered possibly, probably, or definitely drug related in approximately 6% of patients treated with Fosamax 40 mg/day versus approximately 1% of patients treated with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of therapy due to any clinical adverse events occurred in 6.4% of patients with Paget's disease treated with Fosamax 40 mg/day and 2.4% of patients treated with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Post-marketing experience has identified additional adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients considering legal action should be aware that the optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance may be relevant in cases where long-term use contributed to ONJ. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan for each patient based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon, and extensive dental surgery to treat ONJ may exacerbate the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Protect your rights. Start your claim process here.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. Check My Eligibility Now

​

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw. It has been reported in patients taking bisphosphonates, including Fosamax (alendronate) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing. Symptoms include pain, swelling, infection, and exposed bone. Diagnosis requires clinical examination and imaging, often by an oral surgeon.

What legal options do I have if I developed ONJ after taking Fosamax?

Patients who developed ONJ after using Fosamax may consider consulting an attorney to explore legal options. Key factors include the adequacy of warnings provided by the manufacturer, the timeline between Fosamax exposure and ONJ onset, and individual risk factors. The Fosamax label includes a warning about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), but patients may question whether it was sufficient. Documenting medical records and exposure history is crucial for any potential claim.

How long after starting Fosamax can ONJ develop?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability can complicate legal claims, making careful medical and chronological documentation essential.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• fosamax lawsuit update what to know about legal options for Fosamax alendronate

References

1. Fosamax (alendronate) DailyMed Label
2. Fosamax Plus D DailyMed Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

See If I Qualify

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.